CATEGORIES: Featured | Ways to Give

CMT Research: Got a Birthday Coming up?

by | May 26, 2026 | 0 comments

CMT Research: Got a Birthday Coming up?

If your birthday falls between June and August, this message is for you.

What if this year, your birthday did something bigger?

Birthday wishes can become CMT breakthroughs. In just five minutes, you can set up a Facebook Birthday Fundraiser for HNF and let your network do the rest. You’d be surprised who is watching your journey, cheering you on, and ready to give when you show them what matters to you.

No awkward asks. No event planning. Just a few clicks, your birthday, and a cause worth celebrating.

Every dollar raised moves us closer to treatments and a cure for Charcot-Marie-Tooth disease. Real research. Real impact. Started by you, on your birthday.

Start Your Birthday Fundraiser

It’s the best gift you can give, and the easiest one to set up.

🎂 + 🎉 + you = accelerated research!

Learn more on this topic

Related Blog Posts

Double Your Donation

by | Mar 9, 2015 | , | 0 Comments

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

by | Mar 9, 2015 | , | 0 Comments

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

by | Dec 19, 2014 | , , | 12 Comments

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news